It has been well demonstrated by various researchers, including our group, that the constitutive activation of NF-κB in human prostate cancer and prostate cancer xenografts and its subsequent localization into the nucleus is considered highly predictive of disease progression/relapse and resistance to chemotherapy [8,9,10]. This evidence concerns the gene NFKB1 and prostate cancer.